Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2011-06-28
2011-06-28
Chen, Stacy B (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S202100
Reexamination Certificate
active
07968102
ABSTRACT:
The invention relates to Dengue chimeric viruses which are less prone to accumulate point mutations and genetic variations. In these Dengue chimeric viruses, the NS5 gene, which encodes polymerase, has been replaced by the corresponding NS5 sequence of a Yellow Fever virus.
REFERENCES:
patent: 7641907 (2010-01-01), Kinney et al.
patent: 1159968 (2000-05-01), None
patent: WO 93/06214 (1993-04-01), None
International Search Report for PCT/EP2007/050290 mailed May 7, 2007.
Butrapet et al., “Attenuation Markers of a Candidate Dengue Type 2 Vaccine Virus, Strain 16681 (PDK-53), are Defined by Mutations in the 5′ Noncoding Region and Nonstructural Proteins 1 and 3,” Journal of Virology, Apr. 2000, p. 3011-3019, vol. 74, No. 7, American Society for Microbiology.
Guirakhoo et al., “Recombinant Chimeric Yellow Fever-Dengue Type 2 Virus is Immunogenic and Protective in Nonhuman Primates,” Journal of Virology, Jun. 2000, p. 5477-5485, vol. 74, No. 12, American Society for Microbiology.
International Preliminary Report on Patentability for PCT/EP2007/050290 issued Jul. 15, 2008.
Dunnen, et al., “Mutation Nomenclature Extensions And Suggestions To Describe Complex Mutations: A Discussion,” Human Mutation, 2000, pp. 7-12; vol. 15, Wiley-Liss, Inc.
Freestone, D.S., “Yellow Fever Vaccine,” Vaccines, 1995, pp. 741-779, second edition, W. B, Saunders, PA.
Gubler, D.J., “Dengue,” The Arboviruses: Epidemiology and Ecology, 1988, pp. 223-260, vol. 2.
Gubler, D.J., et al., “Dengue and Dengue Hemorrhagic Fever,” 1997, pp. 1-22, CABI International Publishing.
Huang Claire Y., et al., “Chimeric Dengue Type 2 (Vaccine Strain PDK-53)/Dengue Type 1 Virus as a Potential Candidate Dengue Type 1 Virus Vaccine,” Journal of Virology, Apr. 2000, pp. 3020-3028, vol. 74, No. 7, American Society for Microbiology.
Kautner, Ingrid, et al., “Dengue Virus Infection: Epidemiology, Pathogenesis, Clinical Presentation, Diagnosis, and Prevention,” Journal of Pediatrics, Oct. 1997, pp. 516-524, vol. 131, No. 4.
Peyrefitte, Christophe N., “Genetic Characterization of Newly Reintroduced Dengue Virus Type 3 in Martinique (French West Indies),” Journal of Clinical Microbiology, Nov. 2003, pp. 5195-5198, vol. 41, No. 11, American Society for Microbiology.
Pugachev Konstantin V., et al., “High Fidelity of Yellow Fever Virus RNA Polymerase,” Journal of Virology, Jan. 2004, pp. 1032-1038, vol. 78, No. 2, American Society for Microbiology.
Rice, Charles M., et al., “Nucleotide Sequence Of Yellow Fever Virus: Implications For Flavivirus Gene Expression And Evolution,” Science, Aug. 23, 1985, pp. 726-733, vol. 229.
Rigau-Pérez, Jose G., et al., “Dengue and Dengue Haemorrhagic Fever,” The Lancet, Sep. 19, 1998, pp. 971-977, vol. 352.
Rothman Alan, et al., “Immunopathogenesis of Dengue Hemorrhagic Fever,” Virology, 1999, pp. 1-6, vol. 257.
Sabin Albert B., “Research on Dengue During World War II,” The American Journal of Tropicall Medicine and Hygiene, 1952, pp. 30-50, vol. 1, The Williams and Wilkins Company.
Smithburn, Kenneth C., et al., “Immunology of Yellow Fever,” Yellow Fever Vaccination, World Health Organization Monograph Series, 1956, pp. 1-238.
Vaughn, David W., et al., “Dengue in the Early Febrile Phase: Viremia And Antibody Response,” Journal of Infectious Diseases, 1997, pp. 322-330, vol. 176, The University of Chicago.
Vaughn, David W., et al., “Dengue Viremia Titer, Antibody Response Pattern, And Virus Serotype Correlate With Disease Severity,” Journal of Infectious Diseases, 2000, pp. 2-9, vol. 181, Infectious Diseases Society of American.
“WHO Technical Guide,” Dengue Haemorrhagic Fever: Diagnosis, Treatment and Control, 1986, pp. 1-58, World Health Organization, Geneva.
Wu, Shuenn-Jue L., et al., “Human Skins Langerhans Cells Are Targets Of Dengue Virus Infection,” Nature Medicine, Jul. 2000, pp. 816-820, vol. 6, No. 7.
Chen Stacy B
McDonnell Boehnen & Hulbert & Berghoff LLP
Sanofi Pasteur S.A.
LandOfFree
Dengue chimeric viruses does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dengue chimeric viruses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dengue chimeric viruses will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2684088